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Objective. This study evaluated the use of stromal biomarkers CD34 and a smooth muscle actin (a-SMA) to distinguish
verrucous carcinoma (VC) from verrucous hyperplasia (VH).
Study Design. Thirteen VH, 15 VC, 20 squamous cell carcinoma (SCC), and 16 of uninvolved adjacent stroma specimens
were analyzed for a-SMA and CD34 expression by immunohistochemistry.
Results. Stromal a-SMA positivity was observed in 100% (20 of 20) of the SCC and in 93% (14 of 15) of the VC, whereas
none of the VH (0 of 13) or adjacent uninvolved stroma (0 of 16) demonstrated a-SMA reactivity. Stromal CD34 positivity
was observed in 100% (13 of 13) of VH and adjacent stroma (16 of 16), while 20% (3 of 15) of VC and 11% (2 of 18) of
SCC stroma expressed CD34. The SCC and VC groups differed significantly from the VH and uninvolved stroma groups
for both a-SMA and CD34 expression (P < .0001).
Conclusions. Stromal CD34 and a-SMA protein expression patterns may aid in distinguishing between VC and VH in
challenging cases. (Oral Surg Oral Med Oral Pathol Oral Radiol 2014;117:477-482)Verrucous carcinoma (VC) consists of deceptively
bland, broad-based, inwardly undulating epithelium
devoid of the usual cytologic criteria for malignancy.1
Verrucous hyperplasia (VH) is described as a lesion
that resembles VC but differs in that its base lies above
the line connecting the bases of the uninvolved
epithelium on both sides of the lesion.2 This feature
may be difﬁcult or impossible to evaluate, owing to
inadequate segments of surrounding normal tissue or
technical difﬁculties with embedding and cutting. A
lesion exhibiting growth both above and below such a
line creates further diagnostic confusion. Epithelial
features do not clearly resolve the issue, as both lesions
lack malignant cytology. The stroma, however, may
provide an alternative means by which to distinguish
these lesions. The stroma associated with invasive
carcinoma is characterized by a loss of CD34þ dendritic
cells and a gain of a smooth muscle actinepositive
(a-SMAþ) myoﬁbroblasts; the opposite is seen in un-
involved adjacent stroma. These principles hold true
regardless of anatomic location, as previously described
in squamous cell carcinoma (SCC) of the skin,3 cer-
vix,4,5 esophagus,6 and upper aerodigestive tract7,8; in
ductal carcinoma of the breast9-11; and in adenocarci-
noma of the pancreas12 and colon.13 Additionally, a
gradation of these stromal alterations has beenaResident, Department of Pathology, University of Chicago.
bProfessor, Department of Pathology, NorthShore University Health
System.
cProfessor, Department of Pathology, University of Chicago.
Received for publication Nov 6, 2013; returned for revision Dec 11,
2013; accepted for publication Dec 14, 2013.
 2014 Elsevier Inc.
2212-4403
http://dx.doi.org/10.1016/j.oooo.2013.12.401
Open access under CC BY-NC-ND license.described in low- to high-risk intraepithelial lesions of
the breast,9 cervix,4 and oral mucosa.8
The previous reports in the skin and upper aero-
digestive tract include one report of myoﬁbroblasts
in oral VC, but VC and VH have not been specif-
ically addressed.3,7,8 This study was performed to
compare the stromal reactions among conventional
inﬁltrating SCC, VC, VH, and uninvolved adjacent
stroma with regard to CD34 and a-SMA protein
expression.
MATERIALS AND METHODS
After institutional review board approval, 13 VH speci-
mens, 15 VC specimens, and 20 conventional SCC
specimens from mucocutaneous body sites were
retrieved from the pathology archives. Using established
criteria,14 histopathologic interpretation of the formalin-
ﬁxed, parafﬁn-embedded, hematoxylin-eosinestained
sections was performed by 3 pathologists (K.P., J.B.T.,
and M.W.L.) to conﬁrm the diagnosis of VH, VC, or
SCC. Among the cases analyzed, 16 contained tumor-
free stroma for comparison (5 VC, 4 VH, and 7 SCC).
The stroma associated with the lesional epithelium was
deﬁned as tumor stroma, whereas the uninvolved adja-
cent stroma associated with the normal epithelium was
designated as tumor-free stroma.Statement of Clinical Relevance
The differentiation between VH and VC can be
challenging in histopathologic diagnosis. This study
proposes that stromal expression of CD34 and a
smooth muscle actin proteins may aid in dis-
tinguishing between these 2 entities.
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Table I. Stromal patterns of a-SMAþ myoﬁbroblastic
cells
Pattern  þ þþ
Tumor-free 16 0 0
Verrucous hyperplasia 13 0 0
Verrucous carcinoma 1 7 7
Squamous cell carcinoma 0 11 9
a-SMA, a smooth muscle actin.
ORAL AND MAXILLOFACIAL PATHOLOGY OOOO
478 Paral, Taxy and Lingen April 2014Immunohistochemistry
Sections were deparafﬁnized and rehydrated with
xylene and serial dilutions of ethyl alcohol to distilled
water. Tissue sections were incubated in 1  sodium
citrate buffer at a pH of 6 and heated in a steamer
for 20 minutes. Sections were pretreated with
DAKO target retrieval solution S1699 (DAKO North
America Inc, Carpinteria, CA, USA) for a-SMA.
Anti-a-SMA antibody (DAKO North America;
M0851, mouse immunoglobulin G [IgG], dilution
1:100) and anti-CD34 antibody (Leica Microsystems
Inc, Buffalo Grove, IL, USA; NCL-END, mouse IgG,
dilution 1:25) were applied on tissue sections for a
1-hour incubation at room temperature in a humidity
chamber. The antigen-antibody binding was detected
with labeled antimouse polymerehorseradish perox-
idase Envision þ system (K4001; DAKO North
America) and DAB þ chromogen system (K3468;
DAKO North America). Tissue sections were brieﬂy
immersed in hematoxylin for counterstaining. In all
cases, staining of blood vessels served as positive
internal controls.Semiquantitative assessment and statistical analysis
The percentage of immunoreactive tumor-free and
tumor-associated stromal cells excluding vessels was
recorded as follows: , no positive cells; þ, focal
(<50% positive cells); and þþ, strong (>50% positive
cells), as described by Barth et al.7 The data were
analyzed statistically using STATA 12.1 (StataCorp
LP) in the University of Chicago Biostatistics Lab-
oratory. Differences in ordinal immunohistochemical
levels among groups were analyzed by the Kruskal-
Wallis test followed by the Wilcoxon rank sum test for
pairwise comparisons. In addition, because uninvolved
adjacent tumor-free and tumor-associated stroma tis-
sues were frequently evaluated in the same patient,
proportional odds models were ﬁt with an adjusted
variance estimate to allow for the within-patient cor-
relation. Sensitivity and speciﬁcity were calculated
separately.
RESULTS
One hundred percent (20 of 20) of the tumor-associated
stroma from the SCC specimens and 93% (14 of 15)
from the VC cases demonstrated a-SMA positivity
(Table I; Figures 1 and 2). Strong a-SMA staining was
observed in 45% (9 of 20) of SCC and 46% (7 of 15) of
VC, whereas focal staining was seen in 55% (9 of 20)
of SCC and 46% (7 of 15) of VC. Conversely, none of
the VH (0 of 13) or areas of adjacent tumor-free stroma
(0 of 16) demonstrated a-SMA reactivity (Figure 3). All
VH (13 of 13) as well as the adjacent tumor-free stroma
(16 of 16) exhibited CD34 positivity, with 69% (9 of13) of the VH and 81% (13 of 16) of the adjacent
stroma showing strong positivity (Table II). How-
ever, only 20% (3 of 15) of VC expressed CD34, with
all positive cases being focal. Of note, CD34 was
focally lost in association with inﬂammatory inﬁltrates
(Figure 4). The SCC and VC groups differed signiﬁ-
cantly from the VH and tumor-free stroma groups for
both a-SMA and CD34 (P < .0001). There was no
signiﬁcant difference between SCC and VC (P ¼ .91
and P ¼ .41 for a-SMA and CD34, respectively) or
between VH and tumor-free stroma (P ¼ 1.0 and
P ¼ .73 for a-SMA and CD34, respectively). Results
for within-patient correlation were similar to those
of the nonparametric tests (data not shown). Strong
a-SMA positivity combined with complete CD34
negativity was 100% speciﬁc for carcinoma-associated
stroma, whereas diffuse CD34 positivity combined with
complete a-SMA negativity was 100% speciﬁc for
benign-associated stroma. a-SMA was 93% sensitive
for VC-associated stroma, and CD34 was 100% sensi-
tive for adjacent stroma.DISCUSSION
The present series supports a role for combined CD34
and a-SMA analysis in distinguishing VH from VC.
Loss of CD34þ dendritic cells, together with a gain of
a-SMAþ myoﬁbroblasts, supports a diagnosis of VC,
whereas the opposite reaction supports VH. Diffuse
CD34 positivity is strongly indicative of benignity,
and its loss is a sensitive marker for malignant stromal
alterations. CD34 loss is not speciﬁc for malignancy,
however, as inﬂammatory inﬁltrates were noted to
disrupt the dendritic meshwork, a ﬁnding that has
been previously described.7 Nonspeciﬁc CD34 loss
has also been seen in association with scars and
biopsy sites in skin, in breast tissue, and in the upper
aerodigestive tract.7,11,15-17 In the same body sites,
a-SMA positivity has been noted in the stroma of
granulation tissue.7,11,15-17 In the present series, pos-
itivity for a-SMA was seen only in malignant
stroma; however, not all carcinoma cases were posi-
tive for a-SMA. Thus, the discriminatory utility of
immunohistochemistry for VH and VC hinges on the
combined patterns of the 2 markers along with
Fig. 1. A-C, Hematoxylin-eosinestained sections of SCC demonstrating inﬁltrative islands of squamous epithelium showing
cytologic features of malignancy (original magniﬁcation  10,  50, and  200, respectively). D-F, Immunohistochemical
staining for CD34, demonstrating the absence of a meshwork from the stroma surrounding the tumor cells (original
magniﬁcation  10,  50, and  200, respectively). G-I, Immunohistochemical staining for a-SMA demonstrating myoﬁ-
broblasts enveloping the SCC nests (original magniﬁcation  10,  50, and  200, respectively). (SCC, squamous cell car-
cinoma; a-SMA, a smooth muscle actin.)
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manipulation.
In addition to offering a diagnostic adjunct to the
current histologic criteria, these results stimulate
discourse with respect to the biologic relationship
of VH to VC. Whether VH is the same as VC, a
precursor to VC, or a separate entity altogether has
been a subject of debate. Since it was ﬁrst described
in 1980 by Shear and Pindborg,2 VH has been seen
in association with leukoplakia (53%), VC (29%),
epithelial dysplasia (66%), and conventional SCC
(10%),18 but its placement on a spectrum with
these lesions has not been established. Many authors
have suggested that VH and VC are the same en-
tity.18-22 Supporting this perspective is the sugges-
tion that anatomic location inﬂuences whether a
lesion resembles VH or VC.18 Alternatively, VH
may represent a precursor to VC or may be an
entirely separate entity. The results herein suggest
that VH and VC are not the same lesion, as they
evoke opposite stromal reactions. Alterations in thestromal phenotype not only provide helpful diag-
nostic clues in epithelial lesions but also highlight
the importance of the stromal-epithelial relationship.
In fact, recent evidence suggests that alterations of
the stromal compartment alone are sufﬁcient to
induce epithelial malignancy.23 During the transition
from benign to malignant, resident CD34þ dendritic
cells in normal stroma acquire a cancer-activated
phenotype characterized by a-SMA expression.24
The acquisition of smooth muscle actin is a feature
of myoﬁbroblasts, which are prominent in the des-
moplastic reaction to inﬁltrating solid tumors, and it
may be reasonable to attribute the immunostain-
ing pattern for VC to a type of desmoplasia that is
below the level of appreciation by routine micro-
scopy. Supplementing routine histologic assessment
with these 2 simple and widely available immunos-
tains may contribute diagnostic information. Another
diagnostic tool, nuclear cytometry on Feulgen-
stained histologic sections, has been reported as
useful for differentiating VC from benign lesions,25
Fig. 2. A-C, Hematoxylin-eosinestained sections demonstrating VC with its broad-based invasive pegs (original
magniﬁcation  10,  50, and  200, respectively). D-F, Immunohistochemical staining for CD34 demonstrates a
meshwork of reactive cells in association with the adjacent uninvolved stroma (original magniﬁcation  10,  50,
and  200, respectively). Conversely, CD34 reactivity is limited to the vasculature in the tumor-associated stroma.
G-I, Immunohistochemical staining for a-SMA demonstrating a network of slender, bipolar myoﬁbroblasts beneath the
invading rete pegs (original magniﬁcation  10,  50, and  200, respectively). (VC, verrucous carcinoma; a-SMA, a
smooth muscle actin).
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available to most pathologists.
Since its initial description in 1985,26 proliferative
verrucous leukoplakia (PVL) has posed both diag-
nostic and clinical management challenges. PVL is a
condition of unknown etiology that is most often
observed in middle-aged women. Initially, the clin-
ical presentation may be of a singular leukoplakic
lesion that becomes multifocal over time. Impor-
tantly, PVL has been reported to have a high rate
of malignant transformation.26-29 Although several
criteria for PVL have been proposed,30 the diagnosis
of PVL is often made in a retrospective fashion many
years later, after the lesion has progressed to SCC.
Recently, both DNA aneuploidy and the expression
of several candidate protein biomarkers for the pre-
diction of malignant changes in PVL have been
investigated for their utility in the diagnosis of
PVL.31-33 It would be interesting to test the hypoth-
esis that the stromal CD34 and a-SMA expression
patterns might aid in both distinguishing between VHand PVL in challenging cases and predicting which
PVL cases are at most risk for undergoing malignant
transformation.
In conclusion, given that the mainstay of therapy
for either of these lesions is complete surgical
excision, the distinction between the 2 entities may
be more of a histopathologic endeavor rather than a
clinical one. For the pathologist, the signiﬁcance of
distinguishing these 2 entities rests on the ﬁnding
that 20% of VC cases have foci of conventional
SCC, for which the term hybrid tumor is used,34,35
because these hybrid tumors are treated more
aggressively.35 The biologic relationship between
VC and VH has been, and continues to be, a source
of a diagnostic dilemma. This study presents a po-
tential additional step in discriminating between
them.
The authors thank Theodore Karrison, PhD, for his statistical
expertise and Thomas Krausz, MD, FRCPath, for his
inspiration.
Fig. 3. A-C, Hematoxylin-eosinestained sections demonstrating VH that is characterized by hyperplastic, undulating epithelium
conﬁned to the level of the adjacent uninvolved epithelium (original magniﬁcation  10,  50, and  200, respectively). D-F, Immu-
nohistochemical staining for CD34 demonstrates a dendritic meshwork beneath the lesion that is continuous with the uninvolved stroma
and consists of triangular cell bodies with delicate, interdigitating cytoplasmic extensions (original magniﬁcation 10, 50, and 200,
respectively). G-I, Immunohistochemical staining for a-SMA demonstrating negative stromal staining with positive staining of the
vasculature (original magniﬁcation 10, 50, and 200, respectively). (VH, verrucous hyperplasia; a-SMA, a smooth muscle actin.)
Table II. Stromal patterns of CD34þ dendritic cells
Pattern  þ þþ
Tumor-free 0 3 13
Verrucous hyperplasia 0 4 9
Verrucous carcinoma 12 3 0
Squamous cell carcinoma 18 2 0
Fig. 4. Immunohistochemical staining for the CD34þ den-
dritic meshwork demonstrating focal disruption by inﬂam-
matory cell inﬁltrates (asterisk; original magniﬁcation  200).
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